CGAS and myocardial infarction: The inhibitors of cGAS-STING pathway are proposed as potential therapies for AMI and hepatic IRI.586,587,725,726 The deficiency of cGAS triggers M2-like macrophage phenotypes, restricts pathological remodeling, preservers cardiac function and improves the outcome of MI.563 cGAS depletion in platelets or the FDA-approved cGAS-STING inhibitor Palbociclib alleviates myocardial IRI in mice.565 Furthermore, STING inhibitors reduce organ damage in IRI of the heart, kidneys and liver.588,727,728